The Marked Chart Wire · Health
FDA Approval
FDA approves Revolution Medicines pancreatic cancer drug
The FDA has approved daraxonrasib from Revolution Medicines for the treatment of pancreatic cancer.
Learn the basics
New to this? Read: Reading a stock chart
More Health news
Evaxion
Evaxion shares updated results for EVX-01 cancer shot
The biotech firm disclosed new Phase 2 findings for its personalized vaccine, EVX-01. The data indicated robust immune reactions and validated its AI-Immunology platform.
Novartis
Novartis reportedly drops Ionis heart drug after trial setback
Novartis is said to be discontinuing a heart medication developed with Ionis following a late-stage clinical trial failure.
J&J Psoriasis Drug
J&J reports late-stage trial win for psoriasis pill
Johnson & Johnson announced positive results from a late-stage trial of its oral medication for plaque psoriasis and psoriatic arthritis.
Wegovy
Novo Nordisk shares new data on Wegovy for liver disease
Novo Nordisk presented real-world results showing that semaglutide 2.4 mg improved liver markers, body weight, and glucose levels in adults with MASH. The drug outperformed resmetirom in reducing AST and other cardiometabolic indicators.
Measles
Measles infections in US hit 35-year high
American health officials report over 5,000 confirmed measles cases, the most recorded in three and a half decades.
Cognition
Cognition plans mid-2027 trial start for DLB
Cognition outlined a plan to begin Phase III trials for DLB in mid-2027. The company stated it has sufficient cash to operate through the fourth quarter of 2027.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.